1 - 25 of 55 results for author:"Staudt L.M." in Literature citations
Results Customize
› Repeat search in UniProtKB (16)
| Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. Snow A.L., Xiao W., Stinson J.R., Lu W., Chaigne-Delalande B., Zheng L., Pittaluga S., Matthews H.F., Schmitz R., Jhavar S. et al. J. Exp. Med. 209:2247-2261(2012) · Mapped (2) |
| Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Sanda T., Lawton L.N., Barrasa M.I., Fan Z.P., Kohlhammer H., Gutierrez A., Ma W., Tatarek J., Ahn Y., Kelliher M.A. et al. Cancer Cell 22:209-221(2012) · Mapped (4) |
| Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Johnson N.A., Slack G.W., Savage K.J., Connors J.M., Ben-Neriah S., Rogic S., Scott D.W., Tan K.L., Steidl C., Sehn L.H. et al. J. Clin. Oncol. 30:3452-3459(2012) · Mapped (11) |
| Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Yang Y., Shaffer A.L., Emre N.C., Ceribelli M., Zhang M., Wright G., Xiao W., Powell J., Platig J., Kohlhammer H. et al. Cancer Cell 21:723-737(2012) · Mapped (6) |
| Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Kentsis A., Reed C., Rice K.L., Sanda T., Rodig S.J., Tholouli E., Christie A., Valk P.J., Delwel R., Ngo V. et al. Nat. Med. 18:1118-1122(2012) · Mapped (22) |
| The miRNA-17approximately92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Rao E., Jiang C., Ji M., Huang X., Iqbal J., Lenz G., Wright G., Staudt L.M., Zhao Y., McKeithan T.W. et al. Leukemia 26:1064-1072(2012) · Mapped (5) |
| BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Iqbal J., Meyer P.N., Smith L.M., Johnson N.A., Vose J.M., Greiner T.C., Connors J.M., Staudt L.M., Rimsza L., Jaffe E. et al. Clin. Cancer Res. 17:7785-7795(2011) · Mapped (4) |
| MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Steidl C., Shah S.P., Woolcock B.W., Rui L., Kawahara M., Farinha P., Johnson N.A., Zhao Y., Telenius A., Neriah S.B. et al. Nature 471:377-381(2011) · Mapped (9) |
| Oncogenically active MYD88 mutations in human lymphoma. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., Kohlhammer H., Xu W., Yang Y., Zhao H. et al. Nature 470:115-119(2011) · Mapped (9) |
| A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Annunziata C.M., Hernandez L., Davis R.E., Zingone A., Lamy L., Lam L.T., Hurt E.M., Shaffer A.L., Kuehl W.M., Staudt L.M. Blood 117:2396-2404(2011) · Mapped (3) |
| Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Hailfinger S., Lenz G., Ngo V., Posvitz-Fejfar A., Rebeaud F., Guzzardi M., Penas E.M., Dierlamm J., Chan W.C., Staudt L.M. et al. Proc. Natl. Acad. Sci. U.S.A. 106:19946-19951(2009) · Mapped (2) |
| SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Mozos A., Royo C., Hartmann E., De Jong D., Baro C., Valera A., Fu K., Weisenburger D.D., Delabie J., Chuang S.S. et al. Haematologica 94:1555-1562(2009) · Mapped (2) |
| Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. Wilkinson S.T., Fernandez D.R., Murphy S.P., Braziel R.M., Campo E., Chan W.C., Delabie J., Gascoyne R.D., Staudt L.M., Jaffe E.S. et al. Leuk. Lymphoma 50:1875-1878(2009) · Mapped (9) |
| Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. Taylor J.G., Cheuk A.T., Tsang P.S., Chung J.Y., Song Y.K., Desai K., Yu Y., Chen Q.R., Shah K., Youngblood V. et al. J. Clin. Invest. 119:3395-3407(2009) · Mapped (11) |
| Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. Coffey G.P., Rajapaksa R., Liu R., Sharpe O., Kuo C.C., Krauss S.W., Sagi Y., Davis R.E., Staudt L.M., Sharman J.P. et al. J. Cell. Sci. 122:3137-3144(2009) · Mapped (2) |
| CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Rimsza L.M., Chan W.C., Gascoyne R.D., Campo E., Jaffe E.S., Staudt L.M., Delabie J., Rosenwald A., Murphy S.P. Haematologica 94:596-598(2009) · Mapped (9) |
| Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Bidere N., Ngo V.N., Lee J., Collins C., Zheng L., Wan F., Davis R.E., Lenz G., Anderson D.E., Arnoult D. et al. Nature 458:92-96(2009) · Mapped (22) |
| Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Lam L.T., Davis R.E., Ngo V.N., Lenz G., Wright G., Xu W., Zhao H., Yu X., Dang L., Staudt L.M. Proc. Natl. Acad. Sci. U.S.A. 105:20798-20803(2008) · Mapped (11) |
| The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. O'Shea D., O'Riain C., Taylor C., Waters R., Carlotti E., Macdougall F., Gribben J., Rosenwald A., Ott G., Rimsza L.M. et al. Blood 112:3126-3129(2008) · Mapped (32) |
| Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Young K.H., Leroy K., Moller M.B., Colleoni G.W., Sanchez-Beato M., Kerbauy F.R., Haioun C., Eickhoff J.C., Young A.H., Gaulard P. et al. Blood 112:3088-3098(2008) · Mapped (32) |
| Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W., Rosenwald A. et al. Science 319:1676-1679(2008) · Mapped (2) |
| Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Baskar S., Kwong K.Y., Hofer T., Levy J.M., Kennedy M.G., Lee E., Staudt L.M., Wilson W.H., Wiestner A., Rader C. Clin. Cancer Res. 14:396-404(2008) · Mapped (2) |
| Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Wan F., Anderson D.E., Barnitz R.A., Snow A., Bidere N., Zheng L., Hegde V., Lam L.T., Staudt L.M., Levens D. et al. Cell 131:927-939(2007) · Mapped (11) |
| Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Young K.H., Weisenburger D.D., Dave B.J., Smith L., Sanger W., Iqbal J., Campo E., Delabie J., Gascoyne R.D., Ott G. et al. Blood 110:4396-4405(2007) · Mapped (40) |
| Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Wiestner A., Tehrani M., Chiorazzi M., Wright G., Gibellini F., Nakayama K., Liu H., Rosenwald A., Muller-Hermelink H.K., Ott G. et al. Blood 109:4599-4606(2007) · Mapped (5) |